Teva Pharmaceutical Industries (NYSE:TEVA) Sees Unusual Trading Volume in Its Shares

Adjust Comment Print

The firm now has a target price per share of $24 for TEVA. Royal Bank Of Canada decreased their target price on shares of Teva Pharmaceutical Industries Limited from $71.00 to $58.00 and set an "outperform" rating on the stock in a research report on Monday, November 14th.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) recorded a trading volume of 98.31 million shares, above its 90-day volume average of 16.58 million shares. Credit Suisse Group restated a buy rating and set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 17th.

Teva Pharmaceutical Industries Limited (TEVA) stock directed -63.15% toward a lower level throughout a year ago and swapped 7.62% toward a strong spot during past one month.

Teva Pharmaceutical Industries Ltd. named on Monday a new president and CEO, Kare Schultz, a 30-year veteran in pharmaceutical and health care companies.

Teva shares were up 21.14 percent, or $3.27, to $18.76 in late morning trading. Eagle Asset Management Inc who had been investing in Landstar System Inc for a number of months, seems to be less bullish one the $3.95 billion market cap company. The company's 50 day moving average is $20.66 and its 200 day moving average is $29.02. Teva Pharmaceutical Industries Limited has a one year low of $31.90 and a one year high of $59.35.

Miss America victor leaves little to the imagination in TINY bikini round
Mund bested a field of 51 competitors from each state and the District of Columbia during the weeklong of events. Mund, a former Senate intern, said she wants to see more women elected to all levels of government.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. Teva Pharmaceutical Industries Limited had a net margin of 8.81% and a return on equity of 16.75%. The company reported $1.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.36 by $0.02. The Israeli drugmaker has had its stock price and business prospects battered over the a year ago as the generic pricing environment worsens and other threats continue to unfold. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned "Outperform" rating by RBC Capital Markets on Wednesday, July 29. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & global trademark & copyright laws. On Tuesday, September 13 the stock rating was initiated by Atlantic Securities with "Overweight". It turned negative, as 64 investors sold PPG shares while 263 reduced holdings. Focused Wealth Mngmt Incorporated invested in 0.01% or 1,673 shares. Barclays Capital maintained it with "Equal-Weight" rating and $23 target in Monday, August 7 report. Finally, Sterling Investment Advisors Ltd. grew its holdings in Teva Pharmaceutical Industries Limited by 2.6% during the first quarter.

Middlefield Banc Corp.is a bank holding company. That overhaul included job cuts and the restructuring of its business, which last year returned the firm to full-year profit. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. The stock rose 21.75% or $3.37 reaching $18.87 per share.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. Head to IBD Stock Checkup for a closer look at drugmakers with better ratings.

For the past 5 years, Teva Pharmaceutical Industries Limited's EPS growth has been almost -53%. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Comments